ConductScience.org, home

Paper6470751

Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma.

Creagan ET and 6 others. J Clin Oncol, 1984. Cited by 84 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. Papers, record 6470751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6470751

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma.
PubMed
Journal
J Clin Oncol
PubMed
Year
1984
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
84
iCite
Relative citation ratio, by iCite
2.85
iCite
Revised in PubMed
2017-02-10
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Creagan ETE T
2Ahmann DLD L
3Green SJS J
4Long HJH J
5Frytak SS
6O'Fallon JRJ R
7Itri LML M

Source PubMed

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Interferon Type IMajor topic
MelanomaMajor topic
Skin NeoplasmsMajor topic
DNA, Recombinant
Drug Evaluation
Female
Humans
Male
Middle Aged
Prognosis

Source PubMed

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 84 citations.

PMIDTitleJournalYearIn PapersSource
29,236,046Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research.Int J Mol Sci2017https://conductscience.org/library/papers/29236046PubMed
22,220,281Adjuvant therapy: melanoma.J Skin Cancer2011https://conductscience.org/library/papers/22220281PubMed
20,821,040Cancer immunotherapy and nanomedicine.Pharm Res2011https://conductscience.org/library/papers/20821040PubMed
19,959,212The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.Gynecol Oncol2010https://conductscience.org/library/papers/19959212PubMed
8,542,245Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.Med Oncol1995https://conductscience.org/library/papers/8542245PubMed
8,513,453Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients.Cancer Immunol Immunother1993https://conductscience.org/library/papers/8513453PubMed
8,205,559A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.Cancer Immunol Immunother1994https://conductscience.org/library/papers/8205559PubMed
7,681,371Interferon-alpha in malignant and viral diseases. A review.Drugs1993https://conductscience.org/library/papers/7681371PubMed
3,933,818A phase I trial of recombinant gamma interferon in patients with cancer.Cancer Immunol Immunother1985https://conductscience.org/library/papers/3933818PubMed
3,109,737Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects.Cancer Immunol Immunother1987https://conductscience.org/library/papers/3109737PubMed
2,936,447Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study.Cancer Immunol Immunother1986https://conductscience.org/library/papers/2936447PubMed
2,425,443Interferons: current status and future directions of this prototypic biological.Springer Semin Immunopathol1986https://conductscience.org/library/papers/2425443PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6470751

GET https://conductscience.org/api/papers/v1/6470751/authors